> After removal of colon cancer liver metastases, 40-60% live 5 years and 1 in 5 is cured; without surgery, medians of 24-30 months. Sourced data and what changes it.

**Fuente:** https://quenet-torrent.com/en/pathologies/hepatic-tumors/liver-metastases/life-expectancy/

---

Reviewed by [Prof. Fabrizio Panaro](https://quenet-torrent.com/en/our-team/fabrizio-panaro/), hepatobiliary surgeon · Last medical review: July 30, 2026 · 

Prognosis

# Life expectancy with liver metastases

It depends mainly on whether they can be operated on. When colon cancer metastases are removed completely, 40% to 60% of patients live 5 years and about 1 in 5 is cured; with chemotherapy and no surgery, the median is 24 to 30 months.

Get a reply in 24-48h

We assess your case and, if we can treat it, we offer you an appointment.

-   20,000+ operations performed
-   High-complexity surgical techniques
-   Personal attention within 24/48h

The team's track record

## More than 20,000 oncological operations and 30 years of experience

The Quenet Torrent Institute team has decades of international experience in high-complexity oncological surgery and publishes its results in scientific journals.

20,000+ Oncological operations performed

500+ Cytoreduction + HIPEC procedures

30+ Years of international experience

2 sites Teknon Barcelona · Memorial Publio Cordón Madrid

Clinical summary

**Life expectancy with liver metastases** improves substantially with surgical resection: published series of resected colorectal metastases report 5-year survival of **40-60%**, compared with the **16%** 5-year relative survival recorded for colorectal cancer at the distant stage as a whole (SEER, _Colorectal cancer statistics 2026_). At **Quenet-Torrent Institute** (Teknon Barcelona · Memorial Publio Cordón Madrid), the team of Dr. Quenet and Dr. Torrent, supervised by Prof. Panaro, reassesses cases considered unresectable using combined techniques.

## What determines life expectancy with liver metastases?

**Life expectancy with liver metastases** depends on many factors: the organ where the primary tumor started, the number and size of the liver lesions, the presence of disease outside the liver and, above all, whether the patient can undergo surgery with curative intent.

**Surgery is the only treatment with curative potential** for liver metastases. Without surgery, first-line trials in metastatic colorectal cancer report median overall survival of around **24-30 months** with current regimens (TRIBE trial, _N Engl J Med_ 2014; ESMO guideline for metastatic colorectal cancer). With complete resection, published series put 5-year survival between **40% and 60%** for metastases of colorectal origin.

**Liver metastases** are also called **metastatic liver cancer** or secondary liver cancer. The tumour started in another organ, most often the colon or rectum, and has spread to the liver. Primary liver cancer (hepatocellular carcinoma) is a different disease. It starts in the liver cells and has its own prognosis and treatment. The figures on this page refer to metastases, mostly of colorectal origin.

Liver metastases survival rates at a glance

Situation

Published survival

Source

Colorectal metastases, complete resection

40-60% alive at 5 years, 17-25% at 10 years

Tomlinson, _J Clin Oncol_ 2007; Simmonds, _Br J Cancer_ 2006

Initially unresectable, operated after conversion chemotherapy

33% alive at 5 years

Adam, _Ann Surg_ 2004

Neuroendocrine tumours (G1-G2), resected

60-70% alive at 5 years

Resection series, ENETS/NANETS criteria

Breast cancer, resected

25-58% alive at 5 years

Meta-analysis, _The Surgeon_ 2022

Colorectal, modern chemotherapy without surgery

Median 24-30 months (29.8 in TRIBE)

Loupakis, _N Engl J Med_ 2014

Colorectal MSI-H/dMMR, pembrolizumab

54.8% alive at 5 years, median 77.5 months

KEYNOTE-177, _Ann Oncol_ 2025

Colorectal cancer at the distant stage, all patients

16% relative survival at 5 years

SEER, _Colorectal cancer statistics_ 2026

An important point when reading these figures: **median survival** is the time it takes for half of the patients in a series to die, not the time a particular person will live. **5-year survival** is the percentage of patients alive five years after diagnosis or surgery. Both describe groups, and they come from series with very different selection criteria.

## Life expectancy with liver metastases without surgery

When surgery is not possible, the prognosis depends mainly on the response to systemic treatment.

### Without cancer treatment

The historical reference series, from before modern chemotherapy, reported a **median of 4.5 months** in untreated synchronous liver metastases. It is a 1981 figure given for context, not a usual scenario today.

Bengtsson G, et al. _Am J Surg_. 1981;141(5):586-9.

### With systemic chemotherapy

Current regimens reach median overall survival of around **24-30 months**. In the TRIBE trial, FOLFOXIRI plus bevacizumab achieved a median of **29.8 months** compared with 25.8 with FOLFIRI plus bevacizumab.

Loupakis F, et al. _N Engl J Med_. 2014;371(17):1609-18. ESMO guideline for metastatic colorectal cancer.

### With local ablation (without surgery)

In small lesions and favorable locations, radiofrequency or microwave ablation can achieve **prolonged local control**. Guidelines consider it an alternative or complement when complete resection is not feasible, not a routine substitute for surgery.

ESMO guideline for metastatic colorectal cancer. NCCN Guidelines, Colon Cancer.

### With immunotherapy (MSI-H cases)

In tumors with microsatellite instability (MSI-H/dMMR), the 5-year follow-up of the KEYNOTE-177 trial with pembrolizumab reported median overall survival of **77.5 months** and **54.8% of patients alive at 5 years**, compared with 36.7 months with chemotherapy.

Diaz LA, et al. KEYNOTE-177, 5-year follow-up. _Ann Oncol_. 2025.

## Life expectancy with liver metastases with surgery

Surgical resection of liver metastases is the treatment that offers **the highest long-term survival rates** and even cure in selected cases.

### Resected colorectal metastases

5-year survival of **40-60%** in published series after complete resection. At 10 years, the study that defined the concept of cure reported **17-25%** actual survivors, virtually all of them disease-free.

Tomlinson JS, et al. _J Clin Oncol_. 2007;25(29):4575-80. Systematic review of resection series, _Br J Cancer_. 2006.

### Metastases from neuroendocrine tumors

5-year survival of **60-70%** after resection in well-differentiated tumors (G1-G2), where the biology is more favorable. In high-grade tumors the results are clearly worse.

Series of liver resection in NETs in line with ENETS/NANETS criteria.

### Breast metastases

This is the scenario with the widest variation between series: published series report 5-year survival ranging from **25% to 58%**, with medians around **40%**. The disease-free interval and the resection margin are the factors that weigh most.

Systematic review and meta-analysis of liver resection in metastatic breast cancer, _The Surgeon_. 2022.

### Conversion strategies

In initially unresectable tumors, conversion chemotherapy can make them operable. The reference series reported 5-year survival of **33%** after rescue surgery, with 12.5% of initially unresectable patients going on to have surgery.

Adam R, et al. _Ann Surg_. 2004;240(4):644-58.

**Many cases considered unresectable can be operated on with high-complexity techniques such as ALPPS, two-stage surgery or portal vein embolization.**

**Many cases considered unresectable can be operated on with high-complexity techniques such as ALPPS,**

**What is assessed to decide whether a case can be operated on: [resectability criteria for liver metastases](https://quenet-torrent.com/en/blog/liver-metastases-resectability-criteria/).**

**

**About these figures.** All the data on this page come from published studies and clinical guidelines, referenced at the end. They describe **groups of patients** with specific selection criteria, not individual cases. None of these figures can be used to estimate a particular person's prognosis: that depends on the type of tumor, its extent, its molecular biology, the patient's general condition and the response to treatment, and only the medical team treating the case, with the tests in front of them, can assess it. This page is general information and does not replace a medical consultation.

**

**

Prognosis

## Factors that determine life expectancy with liver metastases

Not all liver metastases have the same prognosis. These are the main factors that affect it.

### Origin of the primary tumor

Colorectal metastases have a better surgical prognosis than those from the pancreas, stomach or lung.

### Number and size of lesions

Fewer and smaller lesions mean a greater chance of complete resection and a better prognosis.

### Disease outside the liver

Metastases outside the liver reduce the chances of surgical cure, although they are not always an absolute contraindication.

### Disease-free interval

A long time between the primary tumor and the appearance of metastases is associated with a better prognosis.

### Response to chemotherapy

A good response to prior systemic treatment is an independent favorable prognostic factor.

### Condition of the remaining liver

Enough functional liver tissue must remain after resection to avoid postoperative liver failure.

## Can life expectancy with liver metastases improve?

**Yes.** Progress in surgical techniques and multimodal treatments has significantly improved the prognosis of patients with liver metastases over the last two decades.

Strategies such as **two-stage surgery**, the ALPPS technique, preoperative portal vein embolization or combining resection with ablation have made it possible to operate on patients who were previously considered unresectable, widening the possibilities of long survival.

Assessment at a **specialized, high-volume center** carries a lot of weight: access to complex techniques and a multidisciplinary team can turn palliative treatment into treatment with curative intent.

Why Quenet-Torrent Institute?

## Specialists in complex liver metastasis cases

Many patients come to Quenet-Torrent Institute after being ruled out for surgery at other centers. Our experience allows us to reassess each case from a different perspective.

### Reassessment of unresectable cases

We review cases considered inoperable, looking for surgical strategies that allow resection with curative intent.

### High-complexity techniques

ALPPS, two-stage surgery, portal vein embolization, combined ablation and complex laparoscopic or robotic hepatectomies.

### Multidisciplinary team

Surgeons, oncologists, interventional radiologists and nuclear medicine specialists work together for each patient.

### More than 20,000 operations

This is the surgical experience the team has accumulated, including in high-complexity cases.

[See full treatment](https://quenet-torrent.com/pathologies/hepatic-tumors/liver-metastases/)

Our team

## Surgeons specialized in liver metastases

Surgeons with international training and experience in high-complexity oncological liver surgery.

![Dr. François Quenet](https://quenet-torrent.com/img/Francois-Quenet.webp)

### Dr. François Quenet

Oncological surgeon

[View doctor: Dr. François Quenet](https://quenet-torrent.com/our-team/francois-quenet/)

> "Surgeon with expertise in gastrointestinal and hepatobiliary tumors and in highly difficult operations."

![Dr. Juan José Torrent](https://quenet-torrent.com/img/JuanJose-Torrent.webp)

### Dr. Juan José Torrent

Oncological surgeon

[View doctor: Dr. Juan José Torrent](https://quenet-torrent.com/our-team/juan-jose-torrent/)

> "Specialist in hepatobiliary tumors and complex oncological surgery, including highly difficult liver metastases."

[Meet the whole team](https://quenet-torrent.com/our-team/)

You might also be interested in

## Related pathologies and procedures

-   [Liver metastases: clinical overview](https://quenet-torrent.com/en/pathologies/hepatic-tumors/liver-metastases/)
-   [Colon cancer (primary origin)](https://quenet-torrent.com/en/pathologies/colorectal-tumors/colon-cancer/)
-   [Advanced liver resection techniques](https://quenet-torrent.com/en/procedures/liver-resections/)

### Have you been told your case is inoperable?

Every year we operate on cases of liver metastases and peritoneal carcinomatosis that other centers had ruled out. Cytoreductive surgery and HIPEC can open up treatment options that have not been considered. Before accepting a prognosis, ask for a specialized surgical assessment.

We review your report and your tests, and we tell you frankly whether your case is operable.

[Request a second opinion](https://quenet-torrent.com/en/online-second-opinion/)

Want to see more first? Read [real patient cases](https://quenet-torrent.com/en/real-cases/) and meet the [team that will assess you](https://quenet-torrent.com/en/our-team/).

## Frequently asked questions about life expectancy with liver metastases

The most common questions about prognosis and survival with liver metastases.

### Is metastatic liver cancer the same as liver metastases?

Yes. Metastatic liver cancer, secondary liver cancer and liver metastases all describe a cancer that started in another organ, most often the colon or rectum, and has spread to the liver. Primary liver cancer (hepatocellular carcinoma) starts in the liver cells and has a different prognosis and treatment. When you read a survival figure, check which of the two it refers to.

### What is the survival rate for metastatic liver cancer?

It depends mainly on whether the metastases can be removed. In colorectal origin, 40-60% of patients are alive at 5 years after complete resection (Tomlinson, J Clin Oncol 2007), compared with a 16% 5-year relative survival for colorectal cancer at the distant stage as a whole (SEER). With modern chemotherapy and no surgery, trials report medians of 24 to 30 months.

### How long can you live with liver metastases?

It depends on the treatment received. With modern chemotherapy and no surgery, trials report medians of 24 to 30 months in metastatic colorectal cancer. After complete liver resection, published series report five-year survival of 40-60%, and between 17% and 25% survivors at ten years. These are data from selected groups, not an individual forecast.

### Can liver metastases be cured?

Yes, in selected cases. The study that defined cure in colorectal liver metastases followed 612 operated patients: 102 were still alive at 10 years and 97% of them were disease-free, which puts the real cure rate between 17% and 25% (Tomlinson, J Clin Oncol 2007).

### Which liver metastases have the best prognosis?

Those of colorectal origin and those from neuroendocrine tumors respond best to surgery, with long survival and even cure. Those from the pancreas, stomach or lung have a worse prognosis and the indication for surgery is much more restrictive. The origin of the primary tumor matters as much as the number of lesions.

### Does chemotherapy improve life expectancy?

Yes, significantly. Modern regimens have doubled survival compared with previous decades. In addition, in some patients they shrink the metastases enough to make them operable, which is known as conversion chemotherapy: the aim shifts from controlling the disease to being able to remove it with curative intent.

### What if I am told the metastases are inoperable?

It is worth asking for a second opinion at a specialized center. Many "inoperable" cases can be treated with high-complexity techniques such as ALPPS, two-stage surgery, portal vein embolization or a combination of resection and ablation, which make initially rejected cases operable.

### Is ablation as effective as surgery?

In small lesions, under 2 or 3 centimeters and in favorable locations, the results can be comparable. In other situations, complete surgical resection offers better local control rates. Both techniques are often combined in the same operation to preserve more healthy liver.

### Can I be operated on again if the metastases come back?

**Yes**, in many cases. A second liver resection for recurrence is a valid strategy and offers results similar to the first operation in selected patients. What is assessed is whether the recurrence is resectable, whether enough healthy liver will remain and whether the patient's general condition allows it.

### Where are liver metastases treated in Spain?

At centers with proven experience in high-complexity oncological surgery and a multidisciplinary board. Quenet Torrent Institute, based in Barcelona with a clinical unit at Hospital Memorial Publio Cordón in Madrid, has performed more than 3,000 procedures and publishes its results in international journals.

### What is the best clinic for liver metastases surgery?

There is no single best clinic, but there are objective criteria for comparing centers. There are five: annual surgical volume, complete resection rate, the team's scientific publications, an established multidisciplinary board and availability of high-complexity techniques. At Quenet Torrent Institute we meet those criteria and treat patients from all over Spain and Latin America.

### How do I ask for a second opinion on liver metastases?

By sending us your medical reports, imaging studies (CT, MRI or PET-CT) and the pathology report if you have it. The team assesses the case at the multidisciplinary board and gives you a written report with the recommended plan within 24 to 72 hours. It is best to ask before the first operation: its quality affects the whole prognosis.

References

## Sources of the survival data

Every figure on this page comes from one of these sources. They are listed so that any patient or professional can check them.

1.  Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. _Actual 10-year survival after resection of colorectal liver metastases defines cure_. J Clin Oncol. 2007;25(29):4575-4580. [PubMed 17925551](https://pubmed.ncbi.nlm.nih.gov/17925551/)
2.  Adam R, Delvart V, Pascal G, et al. _Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival_. Ann Surg. 2004;240(4):644-658. [PubMed 15383792](https://pubmed.ncbi.nlm.nih.gov/15383792/)
3.  Loupakis F, Cremolini C, Masi G, et al. _Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer_ (TRIBE trial). N Engl J Med. 2014;371(17):1609-1618. [NEJM](https://www.nejm.org/doi/full/10.1056/NEJMoa1403108)
4.  Diaz LA, Shiu KK, Kim TW, et al. _Pembrolizumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer: 5-year follow-up from KEYNOTE-177_. Ann Oncol. 2025. [Annals of Oncology](https://www.annalsofoncology.org/article/S0923-7534\(24\)04949-4/fulltext)
5.  Bengtsson G, Carlsson G, Hafström L, Jönsson PE. _Natural history of patients with untreated liver metastases from colorectal cancer_. Am J Surg. 1981;141(5):586-589. [PubMed 7223955](https://pubmed.ncbi.nlm.nih.gov/7223955/)
6.  Simmonds PC, Primrose JN, Colquitt JL, et al. _Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies_. Br J Cancer. 2006;94(7):982-999. [British Journal of Cancer](https://www.nature.com/articles/6603033)
7.  Siegel RL, Wagle NS, Jemal A, et al. _Colorectal cancer statistics, 2026_. CA Cancer J Clin. 2026. Relative survival data by stage from the SEER registry. [CA: A Cancer Journal for Clinicians](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.70067)
8.  Cervantes A, Martinelli E, et al. _Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up_. Ann Oncol. [ESMO guideline](https://www.annalsofoncology.org/article/S0923-7534\(26\)00108-0/fulltext)
9.  National Comprehensive Cancer Network. _NCCN Clinical Practice Guidelines in Oncology: Colon Cancer_. [NCCN](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1428)

Last medical review of the content: July 30, 2026, by [Prof. Fabrizio Panaro](https://quenet-torrent.com/en/our-team/fabrizio-panaro/), hepatobiliary surgeon.

**
